Wall Street brokerages forecast that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post ($0.17) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Infinity Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.16). Infinity Pharmaceuticals reported earnings per share of ($0.14) in the same quarter last year, which indicates a negative year-over-year growth rate of 21.4%. The business is scheduled to announce its next quarterly earnings report on Thursday, March 21st.

On average, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.23) per share for the current year, with EPS estimates ranging from ($0.25) to ($0.22). For the next financial year, analysts anticipate that the business will post earnings of ($0.74) per share, with EPS estimates ranging from ($0.79) to ($0.70). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its earnings results on Monday, November 5th. The biotechnology company reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.37. The firm had revenue of $22.00 million during the quarter.

Several analysts have recently issued reports on INFI shares. Zacks Investment Research upgraded Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Tuesday, September 25th. JPMorgan Chase & Co. downgraded Infinity Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Monday, November 12th. Finally, Wells Fargo & Co downgraded Infinity Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, November 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $3.50.

In related news, major shareholder Bvf Partners L. P/Il bought 91,474 shares of the stock in a transaction dated Thursday, November 15th. The stock was acquired at an average price of $1.35 per share, for a total transaction of $123,489.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Value Fund L. P. Biotechnology bought 100,000 shares of the stock in a transaction dated Wednesday, November 28th. The stock was bought at an average price of $1.30 per share, with a total value of $130,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 3,730,634 shares of company stock worth $5,090,055. Company insiders own 11.45% of the company’s stock.

Several hedge funds have recently bought and sold shares of INFI. Acadian Asset Management LLC grew its stake in shares of Infinity Pharmaceuticals by 95.2% in the second quarter. Acadian Asset Management LLC now owns 372,009 shares of the biotechnology company’s stock valued at $711,000 after buying an additional 181,436 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Infinity Pharmaceuticals in the second quarter valued at about $139,000. Dimensional Fund Advisors LP grew its stake in shares of Infinity Pharmaceuticals by 27.0% in the second quarter. Dimensional Fund Advisors LP now owns 932,370 shares of the biotechnology company’s stock valued at $1,781,000 after buying an additional 198,098 shares in the last quarter. Essex Investment Management Co. LLC grew its stake in shares of Infinity Pharmaceuticals by 121.4% in the third quarter. Essex Investment Management Co. LLC now owns 364,401 shares of the biotechnology company’s stock valued at $988,000 after buying an additional 199,796 shares in the last quarter. Finally, Northpointe Capital LLC acquired a new stake in shares of Infinity Pharmaceuticals in the third quarter valued at about $1,433,000. Institutional investors and hedge funds own 52.16% of the company’s stock.

Infinity Pharmaceuticals stock traded down $0.10 during trading hours on Friday, hitting $1.21. The stock had a trading volume of 469,809 shares, compared to its average volume of 855,698. The firm has a market capitalization of $75.63 million, a price-to-earnings ratio of -1.46 and a beta of 2.51. Infinity Pharmaceuticals has a 1-year low of $1.22 and a 1-year high of $2.92.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Further Reading: Earnings Reports

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.